Bilateral asymmetry of quantitative parenchymal kinetics at ultrafast DCE-MRI predict response to neoadjuvant chemotherapy in patients with HER2+ breast cancer

Magn Reson Imaging. 2023 Dec:104:9-15. doi: 10.1016/j.mri.2023.08.003. Epub 2023 Aug 21.

Abstract

Purpose: To assess whether measurement of the bilateral asymmetry of semiquantitative and quantitative perfusion parameters from ultrafast dynamic contrast-enhanced MRI (DCE-MRI), allows early prediction of pathologic response after neoadjuvant chemotherapy (NAC) in patients with HER2+ breast cancer.

Materials and methods: Twenty-eight female patients with HER2+ breast cancer treated with NAC who underwent pre-NAC ultrafast DCE-MRI (3-9 s/phase) were enrolled for this study. Four semiquantitative and two quantitative parenchymal parameters were calculated for each patient. Ipsilateral/contralateral (I/C) ratio (for four parameters) and the difference between (for two parameters) ipsi- and contra-lateral parenchymal kinetic parameters (kBPE) were compared for patients with pathologic complete response (pCR) and those having residual disease. Lasso regression with leave-one-out cross validation was used to determine the optimal combination of parameters for a regression model and multivariable logistic regression was used to identify independent predictors for pCR. Chi-squared test, two-sided t-test and Kruskal-Wallis test were used.

Results: The Ktrans I/C ratio cutoff value of 1.11 had a sensitivity of 83.3% and specificity of 75% for pCR. The ve I/C ratio cutoff value of 1.1 had a sensitivity of 75% and specificity of 81.3% for pCR. The area under the receiver operating characteristic curve of the three-kBPE parameter model, including initial area under the enhancement curve (AUC30) I/C ratio, KtransI/C ratio and ve I/C ratio, was 0.89 with sensitivity of 91.7% at specificity of 81.3%.

Conclusion: Quantitative assessment of bilateral asymmetry kBPE from pre-NAC ultrafast DCE-MRI can predict pCR in patients with HER2+ breast cancer.

Keywords: BPE; Bilateral asymmetry; HER2+ breast cancer; Response to neoadjuvant chemotherapy; Ultrafast DCE-MRI.

MeSH terms

  • Adult
  • Aged
  • Breast Neoplasms* / diagnostic imaging
  • Breast Neoplasms* / drug therapy
  • Contrast Media*
  • Female
  • Humans
  • Kinetics
  • Magnetic Resonance Imaging* / methods
  • Middle Aged
  • Neoadjuvant Therapy*
  • Receptor, ErbB-2* / metabolism
  • Sensitivity and Specificity
  • Treatment Outcome

Substances

  • Contrast Media
  • Receptor, ErbB-2
  • ERBB2 protein, human